- What is 300199.SZ's free cash flow?
- Hybio Pharmaceutical Co., Ltd. (300199.SZ)'s trailing-twelve-month free cash flow is $-9.7 million for the twelve months ended March 31, 2026 — operating cash flow minus capital expenditures. FCF is the strongest signal of a company's ability to fund dividends, buybacks, and growth without external financing. The FCF card on this page shows the annual + quarterly trend.
- What is 300199.SZ's operating cash flow?
- Hybio Pharmaceutical Co., Ltd.'s trailing-twelve-month operating cash flow is $268.1 million for the twelve months ended March 31, 2026 — cash generated from core business activities, before capital expenditures and financing. The OCF card on this page shows the annual and quarterly trend.
- How much does 300199.SZ spend on capital expenditures?
- Hybio Pharmaceutical Co., Ltd. (300199.SZ)'s trailing-twelve-month capital expenditures total $277.8 million for the twelve months ended March 31, 2026. The CapEx card on this page shows the trend over time, revealing how aggressively the company is investing in future growth vs harvesting current operations.
- How current is 300199.SZ's cash flow data?
- Hybio Pharmaceutical Co., Ltd. (300199.SZ)'s cash-flow figures on this page cover the twelve months ended March 31, 2026. They refresh as each new 10-Q and 10-K filing is parsed, typically within 48 hours of SEC submission.
